Fujifilm stock expands ADC manufacturing in Japan

Published on 10/07/2026 at 00:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fujifilm stock adds ADC capacity at its Hirono Plant, with operations scheduled for 2028. Fiscal 2027 first-quarter revenue rose 10.3 percent to JPY 826.5 billion.

Fujifilm, JP3814000000, Illustration mit AI erstellt.

Fujifilm stock (ISIN JP3814000000) was last at JPY 3,424 on the Tokyo Stock Exchange on October 6, 2026, up 0.59 percent from the prior close. The company is expanding its contract manufacturing platform for antibody-drug conjugates, or ADCs, in a move that adds a concrete growth project to a mixed quarterly picture.

ADC capacity starts in 2028

According to Fujifilm on October 6, 2026, the group will install equipment for linker-payloads at the Hirono Plant in Fukushima Prefecture. Operations are scheduled to begin in 2028.

The project is designed to create Japan's first one-stop ADC CDMO service, covering linker-payload production, antibody manufacturing, conjugation and drug-product manufacturing. Fujifilm said the facility will serve pharmaceutical customers from development through commercial production, linking the investment to its healthcare strategy rather than to imaging alone.

Revenue grows as profit falls

Fujifilm's fiscal 2027 first-quarter revenue reached JPY 826.5 billion, a 10.3 percent increase from the prior-year quarter, while operating profit fell 32.0 percent to JPY 51.2 billion. Pixlog reported on October 2, 2026, that net profit attributable to shareholders declined 30.4 percent to JPY 37.4 billion.

The contrast matters for the ADC expansion thesis: sales are advancing, but fixed costs at new biopharmaceutical facilities and other expenses are weighing on near-term earnings. The market therefore has a measurable growth signal in revenue and a measurable execution burden in the 32.0 percent operating-profit decline.

Consensus target stays higher

Pixlog cited a Buy consensus from 12 analysts in its September 20, 2026 analysis, with an average target of JPY 3,955 based on data dated September 7, 2026. That consensus target lies 15.51 percent above the JPY 3,424 price on October 6, 2026, although the target and the market price come from different dates.

The stock's JPY 2,855 to JPY 3,908 52-week range places the latest price 12.38 percent below the high. Market capitalization stood at JPY 4.1 trillion and trading volume was 3,631,100 shares on October 6, 2026.

Results date is November 9

Simply Wall St lists November 9, 2026, as Fujifilm's scheduled fiscal 2027 second-quarter results date. That report should show whether the revenue growth recorded in the first quarter is beginning to offset the cost burden from healthcare capacity expansion.